Vergent Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.vergentbio.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Vergent Bioscience, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT06145048
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase 2 Study of VGT-309 in Lung Cancer
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vergent Bioscience, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05400226
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
News
No news found